Neon Therapeutics, Inc. (NTGN)
(Delayed Data from NSDQ)
$6.13 USD
+0.18 (3.03%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.06 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[NTGN]
Reports for Purchase
Showing records 1 - 10 ( 10 total )
Industry: Medical - Drugs
BioNTech to Acquire Neon Therapeutics; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Drugs
Neon Files CTA for NEO-PTC-01 in Denmark; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Corporate Restructuring and Strategic Shift; Reducing our Rating to Neutral Without a Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
3Q19 Financials Reported; Near-Term Dilution Ahead; Reiterate Buy; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Opdivo SITC Update Appears Encouraging, From Our Vantage Point; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Industry: Medical - Drugs
High-Profile Scientific Publication Highlights Neon''s MHC Class II Prediction Capability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Industry: Medical - Drugs
PFS Data Partially De-Risks NEO-PV-01 in Our View; Reiterate Buy and Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Drugs
Blazing an Algorithmic Trail in Neoantigen Drug Development; Initiating at Buy and $10 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|